OneDigital Investment Advisors LLC bought a new position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 27,903 shares of the company's stock, valued at approximately $615,000.
Several other hedge funds have also modified their holdings of CLBT. JPMorgan Chase & Co. raised its holdings in Cellebrite DI by 21.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 427,655 shares of the company's stock worth $7,202,000 after buying an additional 75,092 shares during the period. Harbor Capital Advisors Inc. increased its position in shares of Cellebrite DI by 65.4% in the fourth quarter. Harbor Capital Advisors Inc. now owns 157,671 shares of the company's stock worth $3,473,000 after acquiring an additional 62,320 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Cellebrite DI during the fourth quarter valued at approximately $9,995,000. State Street Corp lifted its position in shares of Cellebrite DI by 7.3% in the 3rd quarter. State Street Corp now owns 443,700 shares of the company's stock valued at $7,472,000 after acquiring an additional 30,052 shares in the last quarter. Finally, Teacher Retirement System of Texas acquired a new position in Cellebrite DI in the 4th quarter worth approximately $442,000. 45.88% of the stock is owned by hedge funds and other institutional investors.
Cellebrite DI Price Performance
Shares of NASDAQ CLBT opened at $19.64 on Friday. Cellebrite DI Ltd. has a one year low of $10.25 and a one year high of $26.30. The business's 50-day moving average price is $18.73 and its two-hundred day moving average price is $20.13. The company has a market capitalization of $4.70 billion, a P/E ratio of -14.13, a price-to-earnings-growth ratio of 4.27 and a beta of 1.44.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. On average, equities analysts anticipate that Cellebrite DI Ltd. will post 0.3 EPS for the current year.
Analyst Upgrades and Downgrades
CLBT has been the topic of several recent analyst reports. Needham & Company LLC reissued a "buy" rating and set a $28.00 target price on shares of Cellebrite DI in a research note on Wednesday, April 2nd. Lake Street Capital upped their price target on Cellebrite DI from $17.00 to $26.00 and gave the company a "buy" rating in a research report on Friday, February 14th. Finally, JPMorgan Chase & Co. increased their price objective on Cellebrite DI from $24.00 to $28.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 11th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $23.43.
Get Our Latest Report on Cellebrite DI
Cellebrite DI Profile
(
Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Recommended Stories
Want to see what other hedge funds are holding CLBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
